DrugPatentWatch Database Preview
Details for Patent: 9,045,519
Which drugs does patent 9,045,519 protect, and when does it expire?
This patent has twenty-seven patent family members in twenty-three countries.
Summary for Patent: 9,045,519
Title: | N-pyrazole A.sub.2A receptor agonists |
Abstract: | The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart. ##STR00001## |
Inventor(s): | Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata P. (Pune, IN), Belardinelli; Luiz (Palo Alto, CA) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Application Number: | 14/020,736 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 9,045,519
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,045,519
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
7,144,872 | N-pyrazole A.sub.2A receptor agonists | ➤ Sign Up |
7,183,264 | N-pyrazole A2A receptor agonists | ➤ Sign Up |
7,655,637 | N-pyrazole A.sub.2A receptor agonists | ➤ Sign Up |
6,403,567 | N-pyrazole A2A adenosine receptor agonists | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 9,045,519
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 024441 | ➤ Sign Up | |||
Austria | 256141 | ➤ Sign Up | |||
Australia | 7132400 | ➤ Sign Up | |||
Australia | 760806 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |